top of page

PUBLICATIONS

Includes original manuscripts, review articles, abstracts, and poster presentations. These publications are peer-reviewed and often published in high-impact, international scientific journals.

  • S.C.R. Sherratt, R.P. Mason, P. Libby, P.G. Steg, and D.L. Bhatt. (in press). Do patients benefit from omega-3 fatty acids? Cardiovascular Research

  • S.C.R. Sherratt. (2023). REDUCE-IT, biomarkers, and confirmation bias: are we missing the forest for the trees? European Journal of Preventive Cardiology. [PubMed]

  • S.C.R. Sherratt, P. Libby, H. Dawoud, D.L. Bhatt, T. Malinski, and R.P. Mason. (2023). Eicosapentaenoic acid (EPA) reduces pulmonary endothelial dysfunction and inflammation due to changes in protein expression during exposure to particulate matter air pollution. Biomedicine and Pharmacotherapy 162:114629. [PubMed]

  • S.C.R. Sherratt, P. Libby, D.L. Bhatt, and R.P. Mason. (2023). Comparative effects of mineral oil, corn oil, eicosapentaenoic acid, and docosahexaenoic acid in an in vitro atherosclerosis model. Journal of the American Heart Association 12(7):e029109. [PubMed]

  • S.C.R. Sherratt, P. Libby, M.J. Budoff, D.L. Bhatt, and R.P. Mason. (2023). Role of omega-3 fatty acids in cardiovascular disease: the debate continues. Current Atherosclerosis Reports 25(1):1-17. [PubMed]

  • R.P. Mason, S.C.R. Sherratt, and R.H. Eckel. (2023). Omega-3-fatty acids: Do they prevent cardiovascular disease? Best Practice and Reserach Clinical Endocrinology and Metabolism 37(3):101681. [PubMed]

  • Pareek, R.P. Mason, and D.L. Bhatt. (2022). Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides. Expert Opinion on Drug Safety 21(1):31-42. [PubMed]

  • P.M. Ridker, N. Rifai, J. MacFadyen, R.J. Glynn, L. Jiao, P.G. Steg, M. Miller, E.A. Brinton, T.A. Jacobson, J.C. Tardif, C.M. Ballantyne, R.P. Mason, and D.L. Bhatt. (2022). Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1beta, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation 146(5):372-379.  [PubMed]

  • Miller, D.L. Bhatt, P.G. Steg, E.A. Brinton, T.A. Jacobson, L. Jiao, J.C. Tardif, C.M. Ballantyne, M. Budoff, R.P. Mason, and on behalf of the REDUCE-IT investigators. (2022). Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking. European Heart Journal – Cardiovascular Pharmacotherapy. [PubMed]

  • R.P. Mason, S.C.R. Sherratt, and R.H. Eckel. (2022). Rationale for different formulations of omega-3 fatty acids leading to differences in residual cardiovascular risk reduction. Metabolism: Clinical and Experimental 130:155161.  [PubMed]

  • Gaba, D.L. Bhatt, R.P. Mason, M. Miller, S. Verma, P.G. Steg, W.E. Boden, and on behalf of the REDUCE-IT investigators. (2022). Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: a review of key findings from REDUCE-IT. Journal of Clinical Lipidology 16(4):389-402. [PubMed]

  • S.C.R. Sherratt, P. Libby, D.L. Bhatt, and R.P. Mason. (2022). A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes. Prostaglandins, Leukotrienes and Essential Fatty Acids 182:102450.  [PubMed]

  • Singh, D.L. Bhatt, M. Miller, P.G. Steg, E.A. Brinton, T.A. Jacobson, L. Jiao, J.C. Tardif, R.P. Mason, C.M. Ballantyne, and on behalf of the REDUCE-IT investigators. (2022). Consistency of benefit of icosapent ethyl by background statin type in REDUCE-IT. Journal of the American College of Cardiology 79(2):220-222.  [PubMed]

  • M.J. Chapman and R.P. Mason. (2022). Cholesterol crystals and atherosclerotic plaque instability: therapeutic potential of eicosapentaenoic acid. Pharmacology and Therapeutics 240:108237.  [PubMed]

  • R.P. Mason, S.C.R. Sherratt, and R.H. Eckel. (2022). Omega-3-fatty acids: Do they prevent cardiovascular disease? Best Practice and Reserach Clinical Endocrinology and Metabolism:101681.  [PubMed]

  • S.C.R. Sherratt. (2022). Letter by Sherratt Regarding Article, “Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1beta, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy”. Circulation 146(20):e282-e283.  [PubMed]

  • S.C.R. Sherratt, P. Libby, M.J. Budoff, D.L. Bhatt, and R.P. Mason. (2022). Role of omega-3 fatty acids in cardiovascular disease: the debate continues. Current Atherosclerosis Reports.  [PubMed]

  • Z.J. Il’Giovine, J.B. Williams, R.P. Mason, S.C.R. Sherratt, E.M. Hsich, H. Lever, M.R. Mehra, and R.C. Starling. (2021). Kinetics of generic tacrolimus in heart transplantation: A cautionary note. The Journal of Heart and Lung Transplantation 40(7):569-572.  [PubMed]

  • Wang, D. Bhatt, M. Miller, P.G. Steg, E. Brinton, T. Jacobson, S. Ketchum, R. Juliano, L. Jiao, R. Doyle, C. Granowitz, C. Copland, J.C. Tardif, C. Ballantyne, M. Budoff, R.P. Mason, and W. Boden. (2021). Icosapent ethyl reduces ischemic events in patients with high triglycerides and low high-density lipoprotein cholesterol levels: REDUCE-IT high TC/low HDL-C analyses. Journal of the American College of Cardiology 77(18):155. [PubMed]

  • R.P. Mason and R.H. Eckel. (2021). Is there a role for omega-3 fatty acids in cardiovascular disease risk reduction? EClinicalMedicine 39:101096.  [PubMed]

  • Majithia, D.L. Bhatt, A.N. Friedman, M. Miller, P.G. Steg, E.A. Brinton, T.A. Jacobson, S.B. Ketchum, R.A. Juliano, L. Jiao, R.T. Doyle, Jr., C. Granowitz, M. Budoff, R.P. Mason, J.C. Tardif, W.E. Boden, and C.M. Ballantyne. (2021). Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL. Circulation 144(22):1750-1759. [PubMed]

  • S.C.R. Sherratt, H. Dawoud, D.L. Bhatt, T. Malinski, and R.P. Mason. (2021). Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability. Prostaglandins, Leukotrienes and Essential Fatty Acids 173:102337.  [PubMed]

  • S.C.R. Sherratt, R.A. Juliano, C. Copland, D.L. Bhatt, P. Libby, and R.P. Mason. (2021). EPA and DHA containing phospholipids have contrasting effects on membrane structure. Journal of Lipid Research 62:100106.  [PubMed]

  • R.P. Mason and R.H. Eckel. (2021). Mechanistic insights from REDUCE-IT STRENGTHen the case against triglyceride lowering as a strategy for cardiovascular disease risk reduction. American Journal of Medicine 134(9):1085-1090.  [PubMed]

  • R.D. Bhatt, P. Libby, S. Verma, R.P. Mason, and D.L. Bhatt. (2021). The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization. Progress in Cardiovascular Diseases 69:3-10.  [PubMed]

  • S.C.R. Sherratt, M. Lero, and R.P. Mason. (2020). Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence. Current Opinion in Lipidology 31(2):94-100.  [PubMed]

  • R.P. Mason, P. Libby, and D.L. Bhatt. (2020). Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arteriosclerosis, Thrombosis, and Vascular Biology 40(5):1135-1147.  [PubMed]

  • S.C.R. Sherratt, R.A. Juliano, and R.P. Mason. (2020). Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro. Biochimica et Biophysica Acta Biomembranes 1862(7):183254.  [PubMed]

  • V.V. Satokar, W.S. Cutfield, J.G.B. Derraik, M. Harwood, K. Okasene-Gafa, K. Beck, D. Cameron-Smith, J.M. O’Sullivan, G. Sundborn, S. Pundir, R.P. Mason, and B.B. Albert. (2020). Double-blind RCT of fish oil supplementation in pregnancy and lactation to improve the metabolic health in children of mothers with overweight or obesity during pregnancy: study protocol. British Medical Journal Open 10(12):e041015.  [PubMed]

  • T.D. O’Connell, R.P. Mason, M.J. Budoff, A.M. Navar, and G.C. Shearer. (2020). Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites. European Heart Journal Supplement 22(Suppl J):J3-J20.  [PubMed]

  • Wang, S. Verma, R.P. Mason, and D.L. Bhatt. (2020). The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction. Current Diabetes Reports 20(11):65. [PubMed]

  • D.L. Bhatt, M.J. Budoff, and R.P. Mason. (2020). A revolution in omega-3 fatty acid research. Journal of the American College of Cardiology 76(18):2098-2101.  [PubMed]

  • R.P. Mason. (2019). New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease. Current Atherosclerosis Reports 21(1):2.  [PubMed]

  • R.P. Mason, H. Dawoud, S.C.R. Sherratt, M.R. Wagner, and T. Malinski. (2019). Progressive LDL reduction to very low levels improves dimeric nitric oxide synthase, nitric oxide bioavailability and reduces peroxynitrite in endothelial cells during hyperglycemia. American Journal of Pharmacology and Toxicology 14(1):7-16.  [PubMed]

  • S.C.R. Sherratt, P. Villeneuve, E. Durand, and R.P. Mason. (2019). Rosmarinic acid and its esters inhibit membrane cholesterol domain formation through an antioxidant mechanism based, in nonlinear fashion, on alkyl chain length. Biochimica et Biophysica Acta Biomembranes 1861(3):550-555.  [PubMed]

  • S.C.R. Sherratt and R.P. Mason. (2018). Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction. Chemistry and Physics of Lipids 212:73-79.  [PubMed]

  • S.C.R. Sherratt and R.P. Mason. (2018). Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid. Biochemical and Biophysical Research Communications 496(2):335-338.  [PubMed]

  • R.P. Mason, H. Dawoud, R.F. Jacob, S.C.R. Sherratt, and T. Malinski. (2018). Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomedicine and Pharmacotherapy 103:1231-1237.  [PubMed]

  • Sambe, R.P. Mason, H. Dawoud, D.L. Bhatt, and T. Malinski. (2018). Metformin treatment decreases nitroxidative stress, restores nitric oxide bioavailability and endothelial function beyond glucose control. Biomedicine and Pharmacotherapy 98:149-156. [PubMed]

  • O.P. Ganda, D.L. Bhatt, R.P. Mason, M. Miller, and W.E. Boden. (2018). Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. Journal of the American College of Cardiology 72(3):330-343.  [PubMed]

  • J.R. Nelson, W.S. True, V. Le, and R.P. Mason. (2017). Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk? Postgraduate Medicine:1-6.  [PubMed]

  • E.A. Brinton and R.P. Mason. (2017). Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). Lipids in Health and Disease 16(1):23.  [PubMed]

  • Durand, R.F. Jacob, S. Sherratt, J. Lecomte, B. Baréa, P. Villeneuve, and R.P. Mason. (2017). The nonlinear effect of alkyl chain length in the membrane interactions of phenolipids: Evidence by X-ray diffraction analysis. European Journal of Lipid Science and Technology 119(8):1600397. [PubMed]

  • K.M. Borow, R.P. Mason, and K. Vijayaraghavan. (2017). Eicosapentaenoic acid as a potential therapeutic approach to reduce cardiovascular risk in patients with end-stage renal disease on hemodialysis: A review. Cardiorenal Medicine 8(1):18-30.  [PubMed]

  • R.P. Mason, R.F. Jacob, S. Shrivastava, S.C. Sherratt, and A. Chattopadhyay. (2016). Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochimica et Biophysica Acta 1858(12):3131-3140.  [PubMed]

  • V.E. Friedewald, P.H. Jones, P. Mason, R. Roberts, and H. Weintraub. (2016). The Editor’s Round Table: Current Perspectives on Triglycerides and Atherosclerosis. American Journal of Cardiology 117(10):1697-1702.  [PubMed]

  • R.P. Mason, S.C.R. Sherratt, and R.F. Jacob. (2016). Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents. Journal of Cardiovascular Pharmacology 68(1):33-40.  [PubMed]

  • Bate, A. Mathur, H.M. Lever, D. Thakur, J. Graedon, T. Cooperman, R.P. Mason, and E.R. Fox. (2016). Generics substitution, bioequivalence standards, and international oversight: complex issues facing the FDA. Trends in Pharmacological Sciences 37(3):184-191. [PubMed]

  • R.P. Mason, J.J. Corbalan, R.F. Jacob, H. Dawoud, and T. Malinski. (2015). Atorvastatin enhanced nitric oxide release and reduced blood pressure, nitroxidative stress and rantes levels in hypertensive rats with diabetes. Journal of Physiology and Pharmacology 66(1):65-72.  [PubMed]

  • K.M. Borow, J.R. Nelson, and R.P. Mason. (2015). Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis 242(1):357-366.  [PubMed]

  • R.P. Mason and R.F. Jacob. (2015). Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochimica et Biophysica Acta 1848(2):502-509.  [PubMed]

  • R.P. Mason and R.F. Jacob. (2015). Characterization of cholesterol crystalline domains in model and biological membranes using X-ray diffraction. Advances in Experimental Medicine and Biology 842:231-245.  [PubMed]

  • R.P. Mason, R.F. Jacob, J.J. Corbalan, R. Kaliszan, and T. Malinski. (2014). Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes. American Journal of Hypertension 27(3):482-488.  [PubMed]

  • R.P. Mason, R.F. Jacob, J.J. Corbalan, D. Szczesny, K. Matysiak, and T. Malinski. (2013). The favorable kinetics and balance of nebivolol-stimulated nitric oxide and peroxynitrite release in human endothelial cells. BioMed Central Pharmacology and Toxicology 14:48.  [PubMed]

  • R.F. Jacob, M.F. Walter, Y. Self-Medlin, and R.P. Mason. (2013). Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein. Journal of Cardiovascular Pharmacology 62(2):160-166.  [PubMed]

  • R.F. Jacob, M.D. Aleo, Y. Self-Medlin, C.M. Doshna, and R.P. Mason. (2013). 1,2-Naphthoquinone stimulates lipid peroxidation and cholesterol domain formation in model membranes. Investigative Ophthalmology and Visual Science 54(12):7189-7197.  [PubMed]

  • R.P. Mason, R.F. Jacob, R. Kubant, A. Ciszewski, J.J. Corbalan, and T. Malinski. (2012). Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. Journal of Cardiovascular Pharmacology 60(5):467-473.  [PubMed]

  • R.P. Mason, R.F. Jacob, R. Kubant, A.M. Jacoby, F. Louka, J.J. Corbalan, and T. Malinski. (2012). Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants. British Journal of Pharmacology 74(1):141-146.  [PubMed]

  • Ren, R.F. Jacob, Y. Kaulin, P. Dimuzio, Y. Xie, R.P. Mason, G.S. Tint, R.D. Steiner, J.B. Roullet, L. Merkens, D. Whitaker-Menezes, P.G. Frank, M.P. Lisanti, R.H. Cox, and T.N. Tulenko. (2011). Alterations in membrane caveolae and BKCa channel activity in skin fibroblasts in Smith-Lemli-Opitz syndrome. Molecular Genetics and Metabolism 104(3):346-355. [PubMed]

  • R.P. Mason, R.F. Jacob, R. Kubant, M.F. Walter, A. Bellamine, A.M. Jacoby, Y. Mizuno, and T. Malinski. (2011). Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. Journal of Atherosclerosis and Thrombosis 18(9):774-783.  [PubMed]

  • Mizuno, R.F. Jacob, and R.P. Mason. (2011). Combined use of calcium channel blockers and inhibitors of the renin-angiotensin system for treating hypertension. Therapy 8(3):247-260. [PubMed]

  • R.P. Mason. (2011). Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil. Vascular Health and Risk Management 7:405-416.  [PubMed]

  • Mizuno, R.F. Jacob, and R.P. Mason. (2011). Inflammation and the development of atherosclerosis. Journal of Atherosclerosis and Thrombosis 18(5):351-358. [PubMed]

  • S.K. Khan, T. Malinski, R.P. Mason, R. Kubant, R.F. Jacob, K. Fujioka, S.J. Denstaedt, T.J. King, H.L. Jackson, A.D. Hieber, S.F. Lockwood, T.H. Goodin, F.J. Pashkow, and P.F. Bodary. (2010). Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse model. Thrombosis Research 126(4):299-305.  [PubMed]

  • Mizuno, R.F. Jacob, and R.P. Mason. (2010). Advances in pharmacologic modulation of nitric oxide in hypertension. Current Cardiology Reports 12(6):472-480. [PubMed]

  • R.P. Mason, R. Kubant, R.F. Jacob, P. Malinski, X. Huang, F.R. Louka, J. Borowiec, Y. Mizuno, and T. Malinski. (2009). Loss of arterial and renal nitric oxide bioavailability in hypertensive rats with diabetes: effect of beta-blockers. American Journal of Hypertension 22(11):1160-1166.  [PubMed]

  • R.P. Mason, T.D. Giles, and J.R. Sowers. (2009). Evolving mechanisms of action of beta blockers: focus on nebivolol. Journal of Cardiovascular Pharmacology 54(2):123-128.  [PubMed]

  • Self-Medlin, J. Byun, R.F. Jacob, Y. Mizuno, and R.P. Mason. (2009). Glucose promotes membrane cholesterol crystalline domain formation by lipid peroxidation. Biochimica et Biophysica Acta 1788(6):1398-1403. [PubMed]

  • R.P. Mason, R. Kubant, G. Heeba, R.F. Jacob, C.A. Day, Y. Self-Medlin, P. Funovics, and T. Malinski. (2008). Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharmaceutical Research 25(8):1798-1806.  [PubMed]

  • H.P. McNulty, R.F. Jacob, and R.P. Mason. (2008). Biologic activity of carotenoids related to distinct membrane physicochemical interactions. The American Journal of Cardiology 101(10A):20D-29D.  [PubMed]

  • R.P. Mason. (2008). Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management. Drugs 68(7):885-900.  [PubMed]

  • M.F. Walter, R.F. Jacob, R.E. Bjork, B. Jeffers, J. Buch, Y. Mizuno, and R.P. Mason. (2008). Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study. Journal of the American College of Cardiology 51(12):1196-1202.  [PubMed]

  • Funovic, M. Korda, R. Kubant, R.E. Barlag, R.F. Jacob, R.P. Mason, and T. Malinski. (2008). Effect of beta-blockers on endothelial function during biological aging: a nanotechnological approach. Journal of Cardiovascular Pharmacology 51(2):208-215. [PubMed]

  • Mizuno, R.F. Jacob, and R.P. Mason. (2008). Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. American Journal of Hypertension 21(10):1076-1085. [PubMed]

  • H.P. McNulty, J. Byun, S.F. Lockwood, R.F. Jacob, and R.P. Mason. (2007). Differential effects of carotenoids on lipid peroxidation due to membrane interactions: X-ray diffraction analysis. Biochimica et Biophysica Acta 1768(1):167-174.  [PubMed]

  • R.P. Mason, M.F. Walter, C.A. Day, and R.F. Jacob. (2007). A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAIDs. Subcellular Biochemistry 42:175-190.  [PubMed]

  • Yuan, R.J. O’Connell, R.F. Jacob, R.P. Mason, and S.N. Treistman. (2007). Regulation of the gating of BKCa channel by lipid bilayer thickness. The Journal of Biological Chemistry 282(10):7276-7286. [PubMed]

  • R.J. Cenedella, P.S. Sexton, L. Brako, W.K. Lo, and R.F. Jacob. (2007). Status of caveolin-1 in various membrane domains of the bovine lens. Experimental Eye Research 85(4):473-481.  [PubMed]

  • T.N. Tulenko, K. Boeze-Battaglia, R.P. Mason, G.S. Tint, R.D. Steiner, W.E. Connor, and E.F. Labelle. (2006). A membrane defect in the pathogenesis of the Smith-Lemli-Opitz syndrome. Journal of Lipid Research 47(1):134-143.  [PubMed]

  • R.P. Mason and J.R. Cockcroft. (2006). Targeting nitric oxide with drug therapy. Journal of Clinical Hypertension 8(12 Suppl 4):40-52.  [PubMed]

  • R.P. Mason. (2006). Molecular basis of differences among statins and a comparison with antioxidant vitamins. The American Journal of Cardiology 98(11A):34P-41P.  [PubMed]

  • R.P. Mason. (2006). Nitric oxide mechanisms in the pathogenesis of global risk. Journal of Clinical Hypertension 8(8 Suppl 2):31-38.  [PubMed]

  • R.P. Mason, R. Kubant, R.F. Jacob, M.F. Walter, B. Boychuk, and T. Malinski. (2006). Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity. Journal of Cardiovascular Pharmacology 48(1):862-869.  [PubMed]

  • R.P. Mason, M.F. Walter, H.P. McNulty, S.F. Lockwood, J. Byun, C.A. Day, and R.F. Jacob. (2006). Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. Journal of Cardiovascular Pharmacology 47 Suppl 1:S7-14.  [PubMed]

  • R.P. Mason, M.F. Walter, C.A. Day, and R.F. Jacob. (2006). Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. The Journal of Biological Chemistry 281(14):9337-9345.  [PubMed]

  • R.P. Mason. (2005). A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence. Current Drug Targets. Cardiovascular and Haematological Disorders 5(6):489-501.  [PubMed]

  • R.P. Mason. (2005). A rationale for combination therapy in risk factor management: a mechanistic perspective. The American Journal of Medicine 118 Suppl 12A:54-61.  [PubMed]

  • R.P. Mason, L. Kalinowski, R.F. Jacob, A.M. Jacoby, and T. Malinski. (2005). Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 112(24):3795-3801.  [PubMed]

  • R.F. Jacob and R.P. Mason. (2005). Lipid peroxidation induces cholesterol domain formation in model membranes. The Journal of Biological Chemistry 280(47):39380-39387.  [PubMed]

  • R.P. Mason, M.F. Walter, C.A. Day, and R.F. Jacob. (2005). Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. The American Journal of Cardiology 96(5A):11F-23F.  [PubMed]

  • M.F. Walter, R.F. Jacob, B. Jeffers, M.M. Ghadanfar, G.M. Preston, J. Buch, and R.P. Mason. (2004). Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. Journal of the American College of Cardiology 44(10):1996-2002.  [PubMed]

  • M.F. Walter, R.F. Jacob, C.A. Day, R. Dahlborg, Y. Weng, and R.P. Mason. (2004). Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 177(2):235-243.  [PubMed]

  • R.P. Mason, M.F. Walter, and R.F. Jacob. (2004). Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 109(21 Suppl 1):II34-41.  [PubMed]

  • R.J. Cenedella, R.F. Jacob, D. Borchman, D. Tang, A.R. Neely, A. Samadi, R.P. Mason, and P. Sexton. (2004). Direct perturbation of lens membrane structure may contribute to cataracts caused by U18666A, an oxidosqualene cyclase inhibitor. Journal of Lipid Research 45(7):1232-1241.  [PubMed]

  • Davignon, R.F. Jacob, and R.P. Mason. (2004). The antioxidant effects of statins. Coronary Artery Disease 15(5):251-258. [PubMed]

  • R.P. Mason, T.N. Tulenko, and R.F. Jacob. (2003). Direct evidence for cholesterol crystalline domains in biological membranes: role in human pathobiology. Biochimica et Biophysica Acta 1610(2):198-207.  [PubMed]

  • R.P. Mason, P. Marche, and T.H. Hintze. (2003). Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arteriosclerosis, Thrombosis, and Vascular Biology 23(12):2155-2163.  [PubMed]

  • R.P. Mason. (2003). Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research. Cerebrovascular Diseases 16 Suppl 3:11-17.  [PubMed]

  • R.P. Mason and R.F. Jacob. (2003). Membrane microdomains and vascular biology: emerging role in atherogenesis. Circulation 107(17):2270-2273.  [PubMed]

  • R.P. Mason and R.F. Jacob. (2002). X-ray diffraction analysis of membrane structure changes with oxidative stress. Methods in Molecular Biology 196:69-78.  [PubMed]

  • R.F. Jacob, R.J. Cenedella, and R.P. Mason. (2001). Evidence for distinct cholesterol domains in fiber cell membranes from cataractous human lenses. The Journal of Biological Chemistry 276(17):13573-13578.  [PubMed]

  • R.P. Mason, E.G. Olmstead, and R.F. Jacob. (2000). Antioxidant activity of the monoamine oxidase B inhibitor lazabemide. Biochemical Pharmacology 60(5):709-716.  [PubMed]

  • R.F. Jacob, R.J. Cenedella, and R.P. Mason. (1999). Direct evidence for immiscible cholesterol domains in human ocular lens fiber cell plasma membranes. The Journal of Biological Chemistry 274(44):31613-31618.  [PubMed]

  • R.P. Mason, P.R. Leeds, R.F. Jacob, C.J. Hough, K.G. Zhang, P.E. Mason, and D.M. Chuang. (1999). Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. Journal of Neurochemistry 72(4):1448-1456.  [PubMed]

  • R.P. Mason, M.F. Walter, M.W. Trumbore, E.G. Olmstead, Jr., and P.E. Mason. (1999). Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. Journal of Molecular and Cellular Cardiology 31(1):275-281.  [PubMed]

  • T.N. Tulenko, J. Brown, L. Laury-Kleintop, M. Khan, M.F. Walter, and R.P. Mason. (1999). Atheroprotection with amlodipine: cells to lesions and the PREVENT trial. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial. Journal of Cardiovascular Pharmacology 33 Suppl 2:S17-S22.  [PubMed]

  • G.A. Golden, P.E. Mason, R.T. Rubin, and R.P. Mason. (1998). Biophysical membrane interactions of steroid hormones: a potential complementary mechanism of steroid action. Clinical Neuropharmacology 21(3):181-189.  [PubMed]

  • G.A. Golden, R.T. Rubin, and R.P. Mason. (1998). Steroid hormones partition to distinct sites in a model membrane bilayer: direct demonstration by small-angle X-ray diffraction. Biochimica et Biophysica Acta 1368(2):161-166.  [PubMed]

  • T.N. Tulenko, M. Chen, P.E. Mason, and R.P. Mason. (1998). Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis. Journal of Lipid Research 39(5):947-956.  [PubMed]

bottom of page